Sec Form 4 Filing - Tanimoto Sarina @ ARS Pharmaceuticals, Inc. - 2024-03-22

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Tanimoto Sarina 2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [ SPRY] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) CHIEF MEDICAL OFFICER (Last) (First) (Middle) C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120 3. Date of Earliest Transaction (MM/DD/YY) 03/22/2024 (Street) SAN DIEGO, CA92130 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 3,276,854 D Common Stock 03/22/2024 S 1,017 ( 1 ) D $ 9.0298 ( 2 ) 1,745,082 I By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 ( 3 ) Common Stock 03/22/2024 S 1,326 ( 1 ) D $ 9.0132 ( 4 ) 1,996,131 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 ( 5 ) Common Stock 03/25/2024 S 47,635 ( 1 ) D $ 9.1238 ( 6 ) 1,697,447 I By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 ( 3 ) Common Stock 03/25/2024 S 47,632 ( 1 ) D $ 9.1236 ( 7 ) 1,948,499 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 ( 5 ) Common Stock 1,696,494 I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 ( 8 ) Common Stock 4,126,822 I By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Tanimoto Sarina C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO, CA92130 X CHIEF MEDICAL OFFICER Signatures /s/ Kathleen Scott, Attorney-in-Fact 03/26/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. ( 2 )The weighted average sales price for the transaction report was $9.0298,and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. ( 3 )The Reporting Person is trustee of the trust. ( 4 )The weighted average sales price for the transaction report was $9.0132,and the range of prices were between $9.00 and $9.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. ( 5 )The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. ( 6 )The weighted average sales price for the transaction report was $9.1238,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. ( 7 )The weighted average sales price for the transaction report was $9.1236,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. ( 8 )The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.